Boehringer's Expanded Venture Fund: Innovation First, Returns Second
Boehringer Ingelheim more than doubled its venture fund from €100m to €250m, giving BI more access to early innovation via new capital, two new investment managers and a West Coast presence.
You may also be interested in...
The head of the German family-owned firm's venture fund tells Scrip that investing very early in promising start-ups gives Boehringer Ingelheim "a little bit of a head start" on rival pharma companies in identifying technologies that could translate into therapies five years down the line .
Merck & Co. adds to its immuno-oncology pipeline with the acquisition of Rigontec for an upfront payment of €115m, with the three-year-old company offering Merck a unique approach to immunotherapy and a lead candidate currently in Phase I/II trials, the first of its kind in human studies.
The German pharma agreed to pay up to €210m to investigate ViraTherapeutics' lead candidate, VSV-GP, alone and in combination, with an option to buy ViraTherapeutics depending on the outcome of Phase I studies.